Probiodrug — Update 31 March 2016

Probiodrug — Update 31 March 2016

Probiodrug

Analyst avatar placeholder

Written by

Probiodrug

Tolerable SAPHIR delay, full data early 2017

FY15 results

Pharma & biotech

31 March 2016

Price

€24.2

Market cap

€180m

Net cash (€m) at end 2015

21.4

Shares in issue

7.4m

Free float

56%

Code

PBD

Primary exchange

Euronext Amsterdam

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

10.0

(1.2)

31.8

Rel (local)

5.3

(1.2)

46.1

52-week high/low

US$26.5

US$17.5

Business description

Probiodrug is a German biopharmaceutical company developing its clinical pipeline for the treatment of Alzheimer’s disease. Lead product candidate, PQ912, has entered Phase IIa. PQ912 is a small molecule inhibitor of glutaminyl cyclase (QC), which is essential for the formation of pGlu-Abeta. Two further products are in preclinical stages.

Next events

AGM

19 May 2016

Q116 results

12 May 2016

PQ912 first Phase IIa data

End-2016

PQ912 full Phase IIa data

early 2017

Analysts

Jonas Peciulis

+44 (0)20 3077 5728

Lala Gregorek

+44 (0)20 3681 2527

Probiodrug is a research client of Edison Investment Research Limited

With its FY15 results, Probiodrug provided an update on the lead Phase IIa SAPHIR trial, which is well underway. R&D expenses were up year-on-year reflecting increased activities related to the study. The six-month delay was mainly a result of enrolment difficulties, which is not uncommon in Alzheimer’s disease (AD) studies due to increasing competition for the same early patient population. Importantly, measures taken by the company addressed this issue well, in our view. The final results are likely in late Q117 or early Q217 which, if positive, should enable Probiodrug to seek a partnership deal.

Year end

Revenue
(€m)

PBT*
(€m)

EPS*
(c)

DPS
(c)

P/E
(x)

Yield
(%)

12/14

0.0

(11.4)

(2.35)

0.0

N/A

N/A

12/15

0.0

(13.5)

(1.96)

0.0

N/A

N/A

12/16e

0.0

(14.2)

(1.91)

0.0

N/A

N/A

12/17e

0.0

(11.2)

(1.50)

0.0

N/A

N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items.

Well-managed G&A costs, funded likely until readout

While 2015 R&D costs were up by 27% year-on-year to €10.2m (in line with our expectations) reflecting the initiation of the Phase IIa SAPHIR study, G&A expenses were kept under control and stayed flat. Probiodrug has indicated that the net loss for 2016 may be larger than that incurred in 2015 due to additional costs related to SAPHIR. Based on our updated forecasts we believe Probiodrug is funded until readout following the private placement, which raised €13.5m in November 2015.

Enrolment issues in AD studies

SAPHIR is Probiodrug’s lead Phase IIa project with PQ912 targeting early stage AD. The goal is to recruit 110 patients across several European countries and the first patient was recruited in March 2015. According to Probiodrug’s newest enrolment estimates, the first data should be announced around the end of 2016 (mid-2016 previously) with the final results due three to four months later. Patient recruitment problems are not uncommon in AD trials and projection of full recruitment is difficult, as a large AD patient population does not necessarily imply a large accessible patient pool for a specific study (see page 2). As SAPHIR is in full swing, we believe the company has better visibility of the timelines now than it did at the start of the trial.

Valuation: Increased to €242.3m or €32.6/share

Our rNPV-based valuation is increased from €234.7m (€31.5m/share) to €242.3m (€32.6/share) due to rolling the model forward in time, which more than offsets the increase in R&D costs. We previously assumed a partnership deal in 2017, which we continue to include despite the delay. We believe that PQ912 is a highly visible project among the players in the AD field and that the potential deal could happen shortly after the data are released, assuming the results are positive.

R&D progress: Tolerable Phase IIa delay due to enrolment

The key message during Probiodrug’s FY15 results call was that the Phase IIa trial is on track although the safety/tolerability data (primary endpoints) are delayed to end 2016 (previously mid-2016). Exploratory efficacy results (secondary endpoints) should be announced three to four months later. The delay is due to several challenges, including high competition in enrolling treatment-naïve patients. To help counter these challenges, Probiodrug has taken measures including increasing the number of trial sites, but the company emphasized that the quality of the process remains a priority.

Challenges recruiting patients into AD trials are not uncommon

While AD accounts for half of all dementia patients with c 5.2m people affected by AD in Western Europe alone, this is misleading in terms of the patient pool accessible to a specific trial. The first issue is that recently the focus has shifted to clinically established, early stage AD, which is believed to be more susceptible to new treatments. Prodromal stage AD or minimal cognitive impairment (MCI) is also a desirable population for trials, but poses challenges because of screening hurdles as there are no reliable tests to identify those who will convert to clinical AD. As a result, the majority of the ongoing late stage trials try to recruit either early stage AD or those patients who have just been diagnosed. Besides competition access to treatment-naïve patents makes enrolment even more challenging.

Retention of patients and data quality begins with recruitment

The other major issue is retention, ie how many of the enrolled patients actually complete the study, as this affects the intention-to-treat analysis of the trial results. Patients with dementia pose particular problems regarding their retention on study trials, which can be partially solved by study partners – a closely related supervising person, eg spouse or adult children). One overview study published in 2010 analysed 29 clinical trials that investigated patients ranging from MCI to severe AD and found that the percentage of patients who complete the trial varied significantly from 46% to 95%.1 Good retention begins with the enrolment of “quality” patients. As a result, if the trial enrolment is delayed, relaxing the screening criteria in AD patients might seem lucrative, but could be perilous in terms of retention and the quality of the final data (although it might be a good strategy in other indications). Increasing the number of trial sites could potentially be a better strategy in this case. The trade off, however, is higher costs in the short term.

Grill JD, Karlawish J: Addressing the challenges to successful recruitment and retention in Alzheimer’s disease clinical trials. Alzheimer’s Research & Therapy 2010, 2:34.

Large patient population does not necessarily imply large accessible patient pool for a trial

In general, a desirable AD patient profile for the majority of ongoing AD trials is recently clinically validated and early AD, treatment-naïve people with as few co-morbidities as possible. According to World Alzheimer Report 2015 (Alzheimer’s disease International), there were an estimated c 2.6m people newly diagnosed with dementia in North America and Western Europe, of which AD accounts for 60-80% (alzheimer.org) or around 1.8m. Mild AD is estimated to account for around 27% (World Alzheimer Report 2014), which reduces the target population to c 490k. The final size of the accessible patient pool is difficult to estimate, but it could be multiple times less than the figure above, which is due to the fact that most AD patients are older than 75 years of age and are therefore likely to be affected by co-morbidities or are not AD treatment naïve. In addition, geographical distance further limits access to these patients as clinical trials tend to compete for the leading neurology centres.

There are currently 96 active Phase I/II or later stage clinical trials in the US and Europe’s top five countries focused on prodromal or clinical stage AD. In total, these trials are seeking to recruit an impressive 31,818 patients (clinicaltrials.gov). Exhibit 1 shows a breakdown according to stage.

Exhibit 1: Breakdown of total number of AD patients sought by clinical trials per stage

Stage

No of studies

Enrolment target

Phase IV

6

727

Phase III

23

15,151

Phase II/III

11

6,727

Phase II

48

8,873

Phase I/II

8

340

Total

96

31,818

Source: Edison Investment Research, clinicaltrials.gov. Note: Accessed on 23 March 2016. Trials run in North America and Europe’s top five countries.

Financials

R&D spend in 2015 increased to €10.2m (vs €8.0m in 2014) and was largely in line with our expectations of €10.7m. The increase was mainly a result of initiating and conducting the SAPHIR study, which is fully underway. G&A expenses of €3.3m stayed flat year-on-year and were somewhat below our estimate of €3.6m. Accordingly, the net loss increased to €13.5m in 2015 (vs €11.4m in 2014). Probiodrug indicated that the net loss for 2016 may be larger than that incurred in 2015 due to additional costs related to SAPHIR. We believe this may be primarily related to R&D spend, which we adjusted to €11.1m expected in 2016 compared to our previous estimate of €9.8m. Our G&A estimate for 2016 was adjusted only slightly downwards. We continue to expect a licensing deal in 2017 and PQ912-related R&D spend will be borne by a partner.

Probiodrug reported cash of €21.4m at end 2015, which was boosted by the gross proceeds of €13.5m from a private placement in November. Our post-FY15 model suggests that this should be sufficient to fund operations until around mid-2017. According to the latest Probiodrug’s enrolment projections, the first data from SAPHIR may be reported by the end of 2016, while the final results should be released three to four months later. As per our current estimates, existing funding is sufficient to reach the readout. However, it is uncertain whether the company will be required to repay tax provisions of €2.6m; if it does, the company estimates the cash reach is the beginning of Q117. In either case, the readout will be imminent at that point and, in our view, the future operations of Probiodrug will depend on the data rather than on the short-term liquidity situation.

We continue to expect that if the trial results are positive, a licensing deal in 2017 is likely given the high profile of Probiodrug’s R&D programme among the larger players in the AD field. Although our valuation includes risk-adjusted milestones from a partner for PQ912 that could be triggered by licensing and the start of Phase III in 2017 (more details in our initiation report), our financial forecasts do not include any such income. Hence, our forecasts include €5.5m of illustrative financing included as long-term debt on the balance sheet in 2017. This is based on the cash need that we estimate is required to run the business through to the end of 2017.

Valuation

Our Probiodrug valuation is increased to €242.3m (from €234m) or €32.6/share due to rolling our model forwards in time, which more than offset the increase in R&D costs. We previously assumed the deal in 2017 and still maintain this assumption given the six-month delay (which increased R&D costs). Our other assumptions for PQ912 are unchanged. While no value is assigned to the preclinical pipeline given its earlier stage of development, it represents potential upside to our current valuation that could be added as the projects progress into clinical stage. The breakdown of our rNPV valuation, which uses a discount rate of 12.5%, is shown in Exhibit 2.

Exhibit 2: Probiodrug rNPV valuation

Product

Indication

Launch

Peak sales (€m)

Value (€m)

Probability

rNPV (€m)

NPV/Share (€/share)

PQ912

Alzheimer's disease

2022

6,200

1,084.2

20%

220.9

29.7

Net cash

21.4

100%

21.4

2.9

Valuation

 

 

 

1,105.6

 

242.3

32.6

Source: Edison Investment Research, Probiodrug. Note: Peak sales are rounded to the nearest €100m.

Our partnering assumptions are also maintained and include a 15% royalty on global sales. We keep our assumptions of peak sales of c €6.2bn in 2028, assuming launch in 2022, for the treatment of mild AD only. Our peak sales are based on the assumption that PQ912 proves to be disease-modifying and is therefore able to command a premium price. We assign a 20% probability of success, based on the risks associated with AD drug development.


Exhibit 3: Financial summary

€000s

2012

2013

2014

2015

2016e

2017e

December

IFRS

IFRS

IFRS

IFRS

IFRS

IFRS

PROFIT & LOSS

Revenue

 

 

6

0

0

0

0

0

Cost of Sales

0

0

0

0

0

0

Gross Profit

6

0

0

0

0

0

Research and development

(9,255)

(8,004)

(8,008)

(10,158)

(11,105)

(7,669)

EBITDA

 

 

(10,206)

(9,387)

(11,173)

(13,337)

(14,449)

(11,190)

Operating Profit (before amort. and except.)

(10,521)

(9,675)

(11,241)

(13,363)

(14,475)

(11,216)

Intangible Amortisation

(37)

(26)

(26)

(30)

(30)

(26)

Exceptionals

0

0

0

0

0

0

Other

0

0

0

0

0

0

Operating Profit

(10,558)

(9,701)

(11,267)

(13,393)

(14,505)

(11,242)

Net Interest

(314)

(106)

(170)

(112)

293

66

Profit Before Tax (norm)

 

 

(10,835)

(9,781)

(11,411)

(13,475)

(14,182)

(11,150)

Profit Before Tax (FRS 3)

 

 

(10,872)

(9,807)

(11,437)

(13,505)

(14,213)

(11,176)

Tax

(656)

0

0

0

0

0

Profit After Tax (norm)

(11,491)

(9,781)

(11,411)

(13,475)

(14,182)

(11,150)

Profit After Tax (FRS 3)

(11,528)

(9,807)

(11,437)

(13,505)

(14,213)

(11,176)

Average Number of Shares Outstanding (m)

4.1

4.3

4.9

6.9

7.4

7.4

EPS - normalised (EUR)

 

 

(2.84)

(2.30)

(2.35)

(1.96)

(1.91)

(1.50)

EPS - normalised and fully diluted (EUR)

 

(2.84)

(2.30)

(2.35)

(1.96)

(1.91)

(1.50)

EPS - (IFRS) (EUR)

 

 

(2.85)

(2.30)

(2.35)

(1.97)

(1.91)

(1.50)

Dividend per share (EUR)

0.0

0.0

0.0

0.0

0.0

0.0

Gross Margin (%)

100.0

n/a

n/a

n/a

n/a

n/a

EBITDA Margin (%)

n/a

n/a

n/a

n/a

n/a

n/a

Operating Margin (before GW and except.) (%)

n/a

n/a

n/a

n/a

n/a

n/a

BALANCE SHEET

Fixed Assets

 

 

996

425

186

140

84

32

Intangible Assets

67

101

82

56

26

0

Tangible Assets

926

321

101

81

55

29

Investments

3

3

3

3

3

3

Current Assets

 

 

9,009

5,856

21,294

21,726

8,294

3,365

Stocks

18

0

0

0

0

0

Debtors

5

0

0

0

0

0

Cash

7,726

4,421

20,920

21,361

7,929

3,000

Other

1,260

1,435

374

365

365

365

Current Liabilities

 

 

(3,570)

(9,320)

(4,580)

(4,911)

(4,672)

(4,359)

Creditors

(3,570)

(3,974)

(4,580)

(4,911)

(4,672)

(4,359)

Short term borrowings

0

(5,346)

0

0

0

0

Long Term Liabilities

 

 

(1,070)

(1,265)

(929)

(822)

(822)

(6,365)

Long term borrowings

0

0

0

0

0

(5,543)

Other long term liabilities

(1,070)

(1,265)

(929)

(822)

(822)

(822)

Net Assets

 

 

5,365

(4,304)

15,971

16,133

2,884

(7,328)

CASH FLOW

Operating Cash Flow

 

 

(12,090)

(8,477)

(10,540)

(12,149)

(13,725)

(10,538)

Net Interest

22

9

(54)

0

293

66

Tax

28

9

5

2

0

0

Capex

(64)

(4)

(2)

(6)

0

0

Acquisitions/disposals

0

0

0

0

0

0

Financing

9,516

(188)

32,436

12,594

0

0

Dividends

0

0

0

0

0

0

Net Cash Flow

(2,588)

(8,651)

21,845

441

(13,432)

(10,473)

Opening net debt/(cash)

 

 

(10,314)

(7,726)

925

(20,920)

(21,361)

(7,929)

HP finance leases initiated

0

0

0

0

0

0

Other

0

0

0

(0)

0

0

Closing net debt/(cash)

 

 

(7,726)

925

(20,920)

(21,361)

(7,929)

2,543

Source: Edison Investment Research, Probiodrug accounts.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Probiodrug and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Coats Group — Update 31 March 2016

Coats Group

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free